Cocrystal Pharma, Inc. announced a securities purchase agreement of 2,030,458 shares of common stock at a price of $1.97 per share for a gross proceeds of $4,000,000 on April 4, 2023. The transaction will include participation from Fred Hassan and new investor, Frost Gamma Investments Trust. The company will raise two equal investments of $2,000,000 each from the investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | -0.76% | +11.43% | +13.23% |
May. 01 | Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects | CI |
Mar. 28 | Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.23% | 19.99M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- COCP Stock
- News Cocrystal Pharma, Inc.
- Cocrystal Pharma, Inc. announced that it expects to receive $4.000002 million in funding from Frost Gamma Investments Trust and other investor